Cord blood therapy offers hope for long COVID sufferers

NCT ID NCT07332338

First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 20 times

Summary

This study offers expanded access to an experimental treatment called REGENECYTE, made from human umbilical cord blood, for people with long COVID. Participants must be 18 or older, have a confirmed post-COVID condition, and test negative for active COVID-19. The goal is to see if this infusion can help manage ongoing symptoms like fatigue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • D&H National Research Center #1

    AVAILABLE

    Miami, Florida, 33169, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Myrak Research Center Inc.

    AVAILABLE

    Miami Lakes, Florida, 33014, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.